Chemotherapy and Radiotherapy of Gastrointestinal Tumors: Symposium on Cytostatic Drugs and Radiotherapy in Gastroenterology: 11th International Congress of Gastroenterology: Papers - Recent Results in Cancer Research 79 (Hardback)
  • Chemotherapy and Radiotherapy of Gastrointestinal Tumors: Symposium on Cytostatic Drugs and Radiotherapy in Gastroenterology: 11th International Congress of Gastroenterology: Papers - Recent Results in Cancer Research 79 (Hardback)
zoom

Chemotherapy and Radiotherapy of Gastrointestinal Tumors: Symposium on Cytostatic Drugs and Radiotherapy in Gastroenterology: 11th International Congress of Gastroenterology: Papers - Recent Results in Cancer Research 79 (Hardback)

(editor)
£72.00
Hardback 112 Pages / Published: 01/10/1981
  • Not available

This product is currently unavailable.

  • This item has been added to your basket
Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10]. Of the few drugs which are active in the advanced disease, only 5-fluorouracil (5-FU) and razoxane "+-1,2-bis(3,4-dioxopiperazin-1-yl)propane) are suitable for long-term adjuvant treatment [2, 9]. 5-FU has been widely and intensively studied as adjuvant chemotherapy in CRC [7], but there is no unanimity that it has even the marginal influence on survival that has been claimed [3, 10]. Razoxane has not previously been tested for adjuvant or maintenance treatment in CRC. It has however a number of biological activities which might be thought useful in the treatment of residual or minimal tumours [1] and which might therefore make it useful as an adjuvant. Thus it specifically prevents tumour dissemination and metastases in some tumours and normalizes the neovasculature which the tumours induce [6, 8, 11]. The drug is not cytotoxic in the usual sense, does not affect non-dividing cells, and only blocks cell division during a brief period of the cell cycle in late G and/or early mitosis [12]. It does so non-selectively and most cells capable of 2 division examined so far have been affected by the drug. Even affected cells however are not destroyed immediately, but may increase in size and become multinucleate [5].

Publisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
ISBN: 9783540109389
Number of pages: 112
Weight: 400 g

You may also be interested in...

Survival Lessons
Added to basket
Cancer Care
Added to basket
£7.99
Paperback
B is for Breast Cancer
Added to basket
Laws of Medicine
Added to basket
Until Further Notice, I am Alive
Added to basket
Beat Cancer
Added to basket
£14.99
Paperback
Cancer
Added to basket
£12.50
Paperback
Cancer: A Very Short Introduction
Added to basket
Oxford Handbook of Oncology
Added to basket
£34.99
Part-work (fascículo)
The Cancer-Fighting Diet
Added to basket
Radical Remission
Added to basket
Oxford Handbook of Clinical Haematology
Added to basket
£34.99
Part-work (fascículo)
The Emperor of All Maladies
Added to basket
Added Time
Added to basket
£6.99
Paperback
When I Die
Added to basket
£8.99
Paperback

Reviews

Please sign in to write a review

Your review has been submitted successfully.